Moderators: Brad Corr, MD & Stephanie Gaillard, MD

Presentations:

• PIK3CA and ARID1A mutations in recurrent/metastatic cervical cancer: The NRG Oncology/Gynecologic Oncology Group-0240 National Institutes of Health Beau Biden Cancer Moonshot (Anjali Hari, MD)
• Toripalimab combined with bevacizumab and chemotherapy for refractory, recurrent or metastatic cervical cancer: preliminary results of a single-arm, open-label, phase Ⅱ trial ( Alexander Melamed on behalf of Peng Peng, MD)
• Endometrial Cancer Molecular Staging: Updates from AJCC, FIGO, European Guidelines (Alexander Olawaiye, MD)
• Overall survival in a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (Daniela Matei, MD)
• Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (Ursula Matulonis, MD)
• Seminal: Overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib in the SOLO1/GOG 3004 trial (Cara Mathews, MD)
• Anlotinib enhanced the efficacy of pembrolizumab in refractory or recurrent High-Grade Serous Ovarian Cancer by regulating the tumor microenviroment (Xiaochun Zhang, MD)
• Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (Jung-Yu Lee, MD)
• SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (Shannon Westin, MD)